Type 1 diabetes mellitus in adults: high-strength insulin glargine 300 units/ml (Toujeo)

High?strength insulin products such as insulin glargine 300 units/ml (Toujeo) have been developed for people with large daily insulin requirements to reduce the number and volume of injections.
In a randomised controlled trial (RCT) in 549 people with type 1 diabetes, Toujeo had similar efficacy to insulin glargine 100 units/ml (Lantus) in terms of HbA1c reduction, but the basal insulin dose used was higher with Toujeo than with Lantus.

There was no benefit of Toujeo over Lantus in terms of reduced hypoglycaemic events.

The safety profile of Toujeo is largely similar to that of Lantus.

Toujeo is not bioequivalent to Lantus and they are not interchangeable without dose adjustment.

Licenced in UK – Aug 2015.

Further info from Author.

G Mohan.